Reversal of Natural Killer Defect in a Patient with Chédiak–Higashi Syndrome after Bone-Marrow Transplantation

Abstract

To the Editor: The major and apparently selective immunologic defect in patients with Chédiak-Higashi syndrome (CHS) is a profound decrease in the natural killer activity of peripheral leukocytes, as described simultaneously by Roder et al.¹ and by us.² Although it has been claimed that in vitro natural killer activity of leukocytes in CHS can be partially restored by interferon,³ we have been unable to modify the natural killer cytotoxic indexes of four patients with CHS by in vitro addition of interferon, even after a 24-hour incubation in medium containing up to 10,000 units of interferon per milliliter. Furthermore, we have . . .